英菲格拉替尼是什么药？哪儿能买？

Cholangiocarcinoma is a malignant tumor originating from the extrahepatic bile duct, including the bile duct from the porta hepatis to the lower end of the common bile duct. It is a serious and very fatal disease. On May 28, 2021, the U.S. Food and Drug Administration accelerated its approval of infigratinib (Truseltiq), which brings hope to many patients with cholangiocarcinoma. What kind of medicine is that? Where can I buy it?

Infigratinib indications

Infigratinib (Truseltiq) is a small molecule ATP-competitive tyrosine kinase inhibitor of FGFR. Infigratinib (Truseltiq) is indicated for adult patients with previously treated, unresectable locally advanced or metastatic FGFR2 fusion cholangiocarcinoma.

Infigratinib (Truseltiq) is not currently on the market in China, so patients cannot purchase the drug in domestic pharmacies or hospital pharmacies. Patients can purchase the cost-effective Infigratinib that is available overseas. The price of Infigratinib is not fixed due to exchange rate fluctuations and other factors. If patients want to know the latest price of Infigratinib that is available overseas in 2021, they can consult domestic professional overseas medical service companies (such as Medical Companion Travel). Patients can also obtain cost-effective Infigratinib (Truseltiq) through overseas medical service organizations such as Medical Travel, which not only saves them the trouble of going abroad, but also guarantees the purchase of genuine drugs, which is very convenient and fast.

Infigratinib related clinical trials

At the 2020 ASCO meeting, a clinical study of infigratinib (Truseltiq) was released. This is a phase 2, multi-center, single-arm trial clinical study designed to investigate the efficacy of infigratinib (Truseltiq) as a third-line or higher treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. A total of 71 patients were included in the trial, with a median age of 53 years. All patients received infigratinib (Truseltiq) treatment.

The trial results showed that in the case of second-line treatment, the median progression-free survival (PFS) of patients was 4.63 months, and the median PFS of patients who received third-line or above treatment with infigratinib (Truseltiq) was 6.77 months. In terms of objective response rate (ORR), for patients who received third-line or above treatment, the ORR of infigratinib (Truseltiq) was 21.6%. From the above clinical trial data, it can be seen that the therapeutic effect of Infigratinib (Truseltiq) is very significant.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: